Ancor Capital Partners, a Dallas-based private equity firm, announces the acquisition of STATinMED Research, a leading medical technology company in the health economics and outcomes research – HEOR – industry. The transaction was finalized Sep. 7 and represents Ancor’s largest acquisition to date. Terms of the transaction were not disclosed.
As one of the world’s leading HEOR companies, STATinMED is transforming the way health care uses real world data to accelerate research and generate evidence that provides enhanced decision-making capabilities for the market. Using their customized research methodologies and a diverse set of data sources, STATinMED draws on millions of data points to develop strategies that deliver better clinical outcomes, higher cost savings and greater value at every stage of the pharmaceutical product lifecycle. STATinMED collaborates with its clients in the pharmaceutical, biotechnology and health information fields to deliver demonstrable results that allow for greater confidence in marketability, pricing strategies, product development, various treatment mixes, economic vitality, and cost-effectiveness that ultimately results in the better overall quality of patient care.
Founded in 2007 by Onur Baser, Ph.D., STATinMED’s interdisciplinary team includes numerous industry specialists that hold advanced degrees or academic positions with prestigious universities and bring expertise in health economics, pharmacoeconomics, clinical or outcomes research, research design, econometrics, statistics and biostatistics. STATinMED has three U.S. locations – Plano, Texas; Ann Arbor, Michigan; and New York, New York.
“Adding STATinMED Research to the Ancor portfolio complements our long-term growth strategy – taking established, successful companies and accelerating their position in the market,” commented Vic Keller, managing partner at Ancor Capital Partners. “The HEOR industry is a complex and fast-growing discipline. As the nation’s economy continues to be challenged by escalating health care costs, STATinMED has emerged as one of the primary drivers of innovation whose trusted research influences strategic health care decision-making.”
Keller continued, “It is an honor to be part of this extraordinary team of professionals who are doing such important and purposeful work in the health care industry. Dr. Baser and his team have done an outstanding job building, growing and executing the vision of STATinMED. Their passion and leadership have instilled a culture of success that has positioned STATinMED to be the preferred partner for the HEOR needs of major pharmaceutical and health care companies. We are excited for the tremendous market opportunities in front of STATinMED and believe that Ancor’s operational expertise and established resources will help propel STATinMED to the next level.”
“We are excited to partner with Ancor as we execute our next phase of growth,” said Baser, founder and chief scientific officer of STATinMED. “We have an incredibly driven culture and are passionate about providing elite services to our customers. I am confident that Ancor’s strategies will align with our vision, and their extensive experience and resources will position STATinMED to capitalize on the opportunities ahead.”
The transaction was led by Keller. Keller joined Ancor Capital Partners in 2017 and brings over 20 years of experience in establishing, growing and optimizing businesses. Keller will assume the role of chairman at STATinMED effective immediately.
Ancor partnered with Capital Southwest Corporation, CION Investments, Harbert Management Corporation and Dos Rios Partners to finance the acquisition with senior debt and co-invested equity.
This transaction represents the 52nd investment for Ancor Capital Partners.
About Ancor Capital Partners
Ancor Capital Partners, a Dallas-based private equity firm, is focused on helping companies reach their next level of growth. Ancor’s experienced team has the acumen, expertise and resources to invest wisely in existing successful companies through private equity buyouts. As a seasoned operating partner, Ancor works to operationally optimize businesses, maximize growth opportunities and instill a lasting culture. With a proven track record of over 50 successful acquisitions to date, Ancor targets health care, consumer staples, industrial manufacturing, automotive and emerging market businesses. For more information, visit http://www.ancorcapital.com.
About STATinMED Research
Founded in 2007, STATinMED Research is a leading medical technology company in the health economics and outcomes research (HEOR) discipline that provides research, consulting and targeted communications to global pharmaceutical, biotechnology and health information companies. STATinMED Research consultants hold academic positions with prestigious universities and bring multidisciplinary academic and industrial expertise in health economics, pharmacoeconomics, clinical or outcomes research, research design, econometrics, statistics and biostatistics. At the core of STATinMED’s mission is the continuing effort to help customers in the health care industry manage costs and improve the quality of care. Their strategy is to provide decision support tools to help its customers improve clinical and business performance. For more information, visit http://www.statinmed.com/en/.